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This randomized double-blind and placebo-controlled study assessed the pharmacodynamics and
pharmacokinetics of prasugrel in healthy adult Japanese male subjects after single (n ¼ 50) and multiple
(n ¼ 40) oral administration. With a single administration of prasugrel (2e30 mg), the plasma con-
centration of the active metabolite increased rapidly, reached a maximum at 30 min after administration,
and then decreased rapidly within 4 h. The 5 mg and higher doses prevented ADP-induced platelet
aggregation in a dose-dependent manner. Further analyses showed that 30 mg prasugrel exhibited the
peak inhibition, and 20 mg prasugrel showed a nearly equivalent effect. With multiple doses (2.5
e10 mg), the pharmacokinetic parameters on Day 1 and Day 7 were similar, and no accumulation
attributable to multiple dosing was observed. The inhibitory effect on ADP-induced platelet aggregation
increased with doses from 2.5 to 7.5 mg, and reached the peak level at 7.5 mg. Regarding safety, all of the
drug-related adverse events observed were mild, and there were no clinically signiﬁcant bleeding-
related adverse events. This study indicates that a single oral administration of prasugrel at a dose of
up to 30 mg and a maintenance dose of up to 10 mg are tolerated in Japanese healthy subjects.
© 2016 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prasugrel is a new-generation thienopyridine anti-platelet drug.
After oral administration, prasugrel is fully and rapidly hydrolyzed
by intestinal carboxylesterase to intermediate metabolites, most of
which are further metabolized in the small intestine and liver by
CYP P450 into an active metabolite [1]. The active metabolite binds
irreversibly to the platelet P2Y12 receptor [2e4]. Prasugrel is re-
ported to exhibit more potent inhibition of platelet aggregation,
rapid onset of action, and minimal interindividual variability in
efﬁcacy [5e8] as compared with clopidogrel.
Prasugrel is already used for the reduction of atherothrombotic
cardiovascular events in patients undergoing percutaneous coro-
nary intervention in the USA, EU, and other countries. The regimen
consisting of a 60-mg loading dose and 10-mg maintenance doses
plus aspirin has shown a signiﬁcant reduction in cardiovascularyo Co., Ltd. (Tokyo, Japan).
emura).
y of Xenobiotics. Published by Elevents (death, myocardial infarction, and stroke) compared with
clopidogrel in TRITON-TIMI 38 (Trial to Assess Improvement in
Therapeutic Outcomes by Optimizing Platelet Inhibition With
Prasugrel-Thrombolysis in Myocardial Infarction 38) [9]. It was also
reported that prasugrel is associated with an increased risk of TIMI
major bleeding. Based on analyses of prespeciﬁed clinical features
in TRITON-TIMI 38, body weight <60 kg was identiﬁed as one of the
risk factors for bleeding.
Prasugrel active metabolite exposure is increased with
decreased body weight [10e13]. A study in healthy Asian subjects
showed that exposure to the prasugrel active metabolite was
greater and the inhibitory effect on platelet aggregation was more
potent in Asian subjects than in Caucasians [14]. It has also been
conﬁrmed that prasugrel shows a more rapid active metabolite
generation and antiplatelet effect in Chinese subjects than in Cau-
casians [15]. Because the average body weight of Japanese is less
than Caucasians, it is expected that Japanese subjects receive a
lower dose than that prescribed in the USA and EU.
The aim of this study was to assess the safety, pharmacody-
namics, and pharmacokinetics of prasugrel in healthy adult Japa-
nese male subjects after a single and multiple oral administration.sevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
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2.1. Subjects and study design
Both the single administration study and multiple dose study
had a randomized, double-blind, and placebo-controlled design. In
the single administration study, 50 healthy Japanese male subjects
aged 20e40 years [(8 subjects for each dose of prasugrel and 2 for
each placebo) x 5 doses (2, 5, 10, 20, and 30 mg)] were enrolled.
Each dose of study drug or placebo was administered in the
morning after overnight fasting.
In the multiple administration study, 40 healthy Japanese male
subjects aged 20e45 years [(8 subjects for each dose of prasugrel
and 2 for each placebo) x 4 doses (2.5, 5, 7.5, 10 mg)] were enrolled.
The study drug was orally administered once daily for 7 days (after
at least 10 h of fasting on Days 1 and 7, after breakfast on Days 2
through 6).
The present study was conducted in accordance with the
Declaration of Helsinki in compliance with Good Clinical Practice
(GCP) and with the approval of the institutional review board.
Written informed consent to participate in the study was obtained
from subjects before their participation in the study.2.2. Pharmacokinetics
In the single administration study, blood samples were collected
before administration and at 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 h
post-dose for analysis of the plasma concentration of active
metabolite of prasugrel. In the multiple dose study, samples were
collected before administration and at 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12,
and 24 h post-dose on Days 1 and 7. The plasma concentration of
active metabolite of prasugrel was measured using a liquid
chromatography-tandem mass spectrometry (LC-MS/MS) method.
Based on the plasma concentration of the active metabolite, phar-
macokinetic parameters were assessed. An Inertsil ODS-3 column
(G. L Sciences Inc.) was used as the HPLC column. The LC mobile
phase was methanol with 1% formic acid (54:46), and the methanol
and 1% formic acid were mixed using an HPLC pump. The rate of
ﬂow was 0.25 mL/min and the injection volume 10 mL. A quadru-
pole tandem mass spectrometer was used for MS (model API4000;
Applied Biosystems, Inc.). From the chromatogram obtained, the
peak area ratio (Y) for the active metabolite MP and I. Std. was
calculated using the LC-MS/MS data-processing software Analyst.
Then, using the calibration curve obtained by linear regressionwith
the preparation concentration as X and an applied weighting of 1/
X2, quantitative calculations were made by the internal standard
method.
Parameters calculated were area under the plasma concen-
trationetime curve up to the last quantiﬁable time (AUC0-tz), area
under the plasma concentrationetime curve up to inﬁnity (AUC0-
inf), maximum plasma concentration (Cmax), time to reach
maximum plasma concentration (tmax), and terminal elimination
half-life (t1/2) in both studies. In the single administration study,
WinNonlin-Pro version 4.1 (Pharsight Corporation, Mountain View,
CA) was used for calculation of pharmacokinetic parameters, and S-
plus 6.2J for Windows (Mathematical Systems, Inc., Tokyo, Japan)
was used for the data handling. In the multiple administration
study, area under the plasma concentrationetime curve during
dosing interval (AUCtau) and cumulative coefﬁcient (Robs) were also
examined. Robs was calculated as the ratio of AUCtau values on Days
1 and 7. WinNonlin-Pro version 5.0.1 (Pharsight Corporation) was
used for calculation of pharmacokinetic parameters other than Robs.
S-plus 6.2J for Windows (Mathematical Systems, Inc., Tokyo, Japan)
was used for the data handling and calculation of Robs.2.3. Pharmacodynamics
In the single administration study, blood samples were
collected before administration and at 1, 2, 4, 8, 24, 48, 96, and
168 h after administration. In the multiple administration study,
blood sampling was before administration and at 4 h after dosing
on Days 1, 3 and 5, at 1, 4, and 8 h after dosing on Day 7, and at
24, 48, and 96 h after the ﬁnal administration. The pharmaco-
dynamics measurements were determined by the light trans-
mission method in response to 5 and 20 mM of adenosine
diphosphate (ADP). CHRONO-PAR ADP REAGENT (Chrono-Log
Corp., Cat No. 384) was used as ADP. At each measuring point, the
maximum platelet aggregation (MPA) was measured using a
platelet aggregation analyzer (MC Medical Inc., MCM Hematracer
313M) using light transmission. Based on the MPA measured at
each blood-sampling time point after the start of administration,
the IPA with respect to ADP (5, 20 M) was calculated using the
following formula.
IPAð%Þ ¼

MPA at screeningMPA at each measuring point
MPA at screening

 100
In the multiple administration study, the platelet reactivity in-
dex (PRI), as determined by vasodilator-stimulated phosphoprotein
(VASP) phosphorylation assay, was also assessed. The PRI was
calculated for each blood-sampling time point following the start of
administration using the following formula.
PRI ¼

MFIPGE1 MFIADP
MFIPGE1

 100
MFIPGE1 ¼MFIðT1Þ MFIðT3Þ
MFIADP ¼MFIðT2Þ MFIðT3Þ
MFI is mean ﬂuorescence intensity; PGE1, prostaglandin E1;
MFI(T1), the value of MFI after stimulating the sample with PGE1,
when stained with anti-phosphorylated VASP antibodies;
MFI(T2), the value of MFI after stimulating the sample with ADP
and PGE1, when stained with anti-phosphorylated VASP anti-
bodies; and MFI(T3), the value of MFI after stimulating the
sample with ADP and PGE1, when stained with negative control
antibodies.2.4. Evaluation of bleeding times
The bleeding time was measured by the Ivy method. In the
single dose study, bleeding time was measured before adminis-
tration and at 4, 24, and 168 h after dosing. In the multiple
administration study, it was measured before administration, at 4 h
after dosing on Days 1 and 7, at 24 h after dosing on Day 7, and at
168 h after the ﬁnal administration.2.5. Safety
The safety and tolerability of prasugrel were evaluated by
assessing the incidence of adverse events. In the single adminis-
tration study, the incidence of adverse events from the time of
administration to 168 h after dosing was evaluated. In the multiple
dose study, evaluation period of adverse events was from Day
1e96 h after the ﬁnal dosing.
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Scatter plots of AUC0-tz and Cmax versus dose were prepared and
these parameters were ﬁtted to a powermodel. By linear regression
analysis using the power model [log Yij ¼ a þ b logXi (Xi: dose; Yij:
pharmacokinetic parameter)], the estimates of a and b as well as
their two-sided 95% conﬁdence intervals (CI) were calculated.
For IPA obtained at each blood sampling point for each subject,
summary statistics were calculated by dose, and by blood sampling
time point, and graphs of the time-course were prepared. The
placebo group and each dose group were compared using Dun-
nett's test by blood sampling time point. The signiﬁcance level was
set at 5%. For PRI, summary statistics were calculated by dose and
by time point to show the time-course. The correlation between IPA
and AUC0-tz was shown by scatter plot.
3. Results
3.1. Disposition of subjects
In the single administration study, 50 healthy adult Japanese
male subjects were enrolled and received the study drug. The mean
ages of the groups (placebo group, 2 mg, 5 mg, 10 mg, 20 mg, and
30 mg group) were 26.4 ± 7.6, 29.3 ± 6.4, 30.3 ± 8.1, 33.4 ± 7.4,
24.6 ± 5.8, and 25.5 ± 6.3 years (mean ± SD), respectively, and the
mean body weight, 63.6 ± 5.2, 66.1 ± 4.4, 58.7 ± 7.8, 60.5 ± 4.7,
60.0 ± 4.2, and 65.1 ± 6.2 kg. However, the data of one subject in the
10 mg prasugrel group were excluded from the pharmacokinetics
and pharmacodynamics data sets because the subject received
treatment with various medications for acute pharyngitis and
tonsillitis one day after prasugrel administration. Thus, the phar-
macokinetics analysis included 39 subjects and the pharmacody-
namics, 49 subjects.
In the multiple administration study, 40 healthy adult Japanese
male subjects were enrolled and received the study drug, and all of
the subjects completed the study. The mean ages of the groups
(placebo group, 2.5 mg, 5 mg, 7.5 mg, and 10 mg group) were
24.5 ± 4.3, 24.4 ± 5.4, 24.1 ± 5.1, 27.5 ± 6.6, and 27.0 ± 4.0 years
(mean ± SD), respectively, and the mean body weight, 61.8 ± 5.4,
65.4 ± 7.9, 64.1 ± 5.6, 62.5 ± 6.3, and 61.7 ± 7.7 kg. The demographic
and baseline characteristics showed no bias that would affect the
results observed between each group.
3.2. Pharmacokinetics
In the single administration study, the plasma concentration of
the active metabolite increased rapidly after administration in all
dose groups, reached a maximum at 30 min after administration,
and then decreased rapidly within 4 h. The active metabolite was
below the lower quantiﬁcation limit in all subjects by 24 h after
administration (Fig. 1a).
The pharmacokinetics parameters of the active metabolite are
shown in Table 1. The AUC0-tz, and Cmax of the active metabolite
increased with dose. However, in the analysis using the power
model, no dose proportionality was observed for any parameter. No
dose-related change was observed in tmax, but t1/2 increased with
dose.
In the multiple administration study, the plasma concentration
of the active metabolite on Day 7 increased rapidly after dosing as
seen on Day 1, reached a maximum at 30 min after administration,
and decreased rapidly within 4 h. The active metabolite was below
the lower quantiﬁcation limit in all subjects by 24 h after the ﬁnal
administration (Fig. 1b and c).
The pharmacokinetics parameters on Day 7 were also similar to
those obtained on Day 1, regardless of the dose (Table 2). The Robsvalue showed no accumulation attributable to multiple dosing.
Both AUC0-tz and Cmax increased with dose in the dose range of
2.5e7.5 mg. In contrast, AUC0-tz and Cmax of the 10 mg group were
lower than those of the 7.5 mg group.3.3. Pharmacodynamics
In the single administration study, the IPA with 20 mM ADP
increased with dose and a rapid onset of anti-platelet effect was
observed. The IPA reached a maximum by 4 h after administration.
The levels of IPA at 4 h after the prasugrel administration of 5, 10,
20, and 30mgwere 14.0%, 40.9%, 64.8%, and 71.2%, respectively, and
these inhibitory effects were signiﬁcantly greater than in the pla-
cebo group (Fig. 2a). The IPA was maintained at almost constant
levels up to 24 h after administration, and then decreased gradually
up to 168 h after administration. The time-course pattern of IPA in
response to 5 mMADPwas similar to that with 20 mMADP (data not
shown).
In the multiple administration study, the inhibitory effect on
platelet aggregation induced by ADP 20 mM reached the maximum
by Day 7, and then gradually decreased until 96 h after the last
dosing. The peak levels of IPA after the prasugrel administration of
2.5, 5, 7.5, and 10 mg were 24.6%, 60.4%, 68.6%, and 71.7%, respec-
tively. In the comparison between the placebo and each dose group
at each time point, a signiﬁcant increase in IPA was observed from
4 h on Day 1e96 h after the last administration in the 5 mg and
higher dose groups. The inhibitory effect on Day 7 was enhanced
with doses from 2.5 to 7.5 mg (Fig. 2b). The time-course pattern of
IPA in response to 5 mM ADP was similar to that with 20 mM ADP
(data not shown).
Also PRI showed a signiﬁcant decrease in comparison with the
placebo, from 4 h after dosing on Day 1 to the post-study exami-
nation in the 7.5 and 10 mg groups. PRI reached maximum inhi-
bition at 1e8 h after administration on Day 7 in all dose groups, and
then gradually increased until 96 h after completion of adminis-
tration. The minimum PRI values of 2.5, 5, 7.5, and 10 mg groups
(61.4%, 27.0%, 14.1%, and 2.6%, respectively) decreased as the pra-
sugrel dose increased (Fig. 2c).
Fig. 2d shows the scatter plots of AUC0-tz and IPA after single
administration of prasugrel. AUC0-tz increased dose-dependently in
doses from 2 mg to 30 mg, whereas IPA showed a dose-dependent
increase from 2 mg to 20 mg but remained at the same level be-
tween 20 mg and 30 mg. Fig. 2e shows the scatter plots of AUC0-tz
and IPA at Day 7 after multiple administration of prasugrel. AUC0-tz
increased dose-dependently in doses from 2.5 mg to 7.5 mg.
However, AUC0-tz at 10 mg was lower than that at 7.5 mg. IPA
showed a dose-dependent increase from 2.5 mg to 7.5 mg, but
remained at the same level between 7.5 mg and 10 mg.3.4. Bleeding time
In the single administration study, the bleeding time before
administration in each dose group was 99.0e132.5 s. There was no
signiﬁcant difference in baseline bleeding time among dose groups;
after administration, the placebo, 2 mg, and 5 mg groups showed
little change, but the 10 mg and higher dose groups showed a
tendency for prolonged bleeding time. The peak level of bleeding
time of 10 mg, 20 mg, and 30 mg groups were 184.0, 252.5, and
287.5 s. In all groups, the bleeding time returned to the baseline
level within 168 h after administration (Fig. 3a).
In the multiple administration study, the baseline of bleeding
time was 94.5e123.5 s. After administration, 5 mg and higher dose
groups showed a tendency for prolonged bleeding time. The peak
level of bleeding time of 5mg, 7.5mg, and 10mg groupswere 175.0,
Fig. 1. Plasma concentrations of active metabolite of prasugrel after a) a single administration, and b) Day 1 and c) Day7 in multiple administration study. Data are arithmetic
means ± standard deviation.
Table 1
Pharmacokinetic parameters for the active metabolite of prasugrel after a single administration.
AUC0-tz (ng$h/mL) AUC0-inf (ng$h/mL) Cmax (ng/mL) tmax (h) t1/2 (h)
2 mg (n ¼ 8) 16.9 (29.4) 18.8 (26.3) 20.9 (35.3) 0.50 [0.25e1.00] 0.7 (37.9)
5 mg (n ¼ 8) 68.6 (21.4) 70.4 (21.8) 64.0 (58.9) 0.50 [0.50e1.50] 1.9 (42.7)
10 mg (n ¼ 7) 159.2 (23.9) 163.0 (23.9) 163.2 (63.3) 0.50 [0.25e1.50] 4.2 (31.3)
20 mg (n ¼ 8) 357.5 (11.4) 365.4 (11.1) 391.7 (26.4) 0.50 [0.25e1.00] 5.8 (25.3)
30 mg (n ¼ 8) 686.4 (20.8) 695.4 (20.6) 538.6 (47.5) 0.75 [0.50e2.00] 6.0 (25.8)
AUC0-tz, area under the plasma concentrationetime curve from time 0 to last measurable concentration.
AUC0-inf, area under the plasma concentrationetime curve up to inﬁnity; Cmax, maximum plasma concentration; tmax, time to Cmax; t1/2, terminal elimination half-life.
Values are the geometric mean (percentage coefﬁcient of variation) for AUC0-tz, AUC0-inf, Cmax, t1/2; median [range] for tmax.
Table 2
Pharmacokinetic parameters for the active metabolite of prasugrel after multiple administrations.
AUC0-tz (ng$h/mL) AUCtau (ng$h/mL) Cmax (ng/mL) tmax (h) t1/2 (h) Robs
2.5 mg (n ¼ 8) Day 1
Day 7
25.0 (34.4)
29.7 (40.1)
26.2 (31.5)
30.4 (38.7)
29.6 (38.7)
29.8 (76.3)
0.50 [0.25e0.50]
0.50 [0.25e0.50]
0.6 (31.2)
1.0 (31.7)
e
1.2 (17.3)
5 mg (n ¼ 8) Day 1
Day 7
71.3 (18.0)
76.8 (19.9)
72.4 (17.9)
78.1 (20.0)
73.1 (31.9)
72.7 (50.1)
0.50 [0.25e1.00]
0.50 [0.50e1.00]
2.2 (33.5)
2.6 (50.4)
e
1.1 (7.0)
7.5 mg (n ¼ 8) Day 1
Day 7
131.3 (12.8)
142.0 (13.0)
133.3 (12.8)
145.8 (12.5)
148.5 (12.2)
138.6 (12.5)
0.50 [0.50e1.00]
0.50 [0.25e1.00]
3.0 (24.8)
4.8 (38.0)
e
1.1 (7.4)
10 mg (n ¼ 8) Day 1
Day 7
66.9 (32.2)
69.1 (28.5)
67.7 (32.2)
70.3 (29.5)
73.0 (40.6)
70.7 (34.6)
0.50 [0.50e1.50]
0.50 [0.25e0.50]
1.4 (46.5)
2.1 (98.0)
e
1.1 (12.4)
AUC0-tz, area under the plasma concentrationetime curve from time 0 to last measurable concentration.
AUCtau, area under the plasma concentrationetime curve during dosing interval; Cmax, maximum plasma concentration; tmax, time to Cmax; Robs, cumulative coefﬁcient; t1/2,
terminal elimination half-life.
Values are the geometric mean (percentage coefﬁcient of variation) for AUC0-tz, AUCtau, Cmax, t1/2, Robs; median [range] for tmax.
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Fig. 2. Mean (±standard deviation) inhibition of platelet aggregation to 20 mM ADP-induced platelet aggregation after a) single and b) multiple administration of prasugrel. c) The
time course of platelet reactivity index obtained from the vasodilator-stimulated phosphoprotein measurement in multiple dose study. Scatter plots of AUC0-tz and IPA after d) single
and e) multiple administration of prasugrel. *P < 0.05, **P < 0.01, and yP < 0.001 versus placebo group. IPA, inhibition of platelet aggregation; PRI, platelet reactivity index; AUC0-tz,
area under the curve up to the last quantiﬁable time.
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baseline level within 168 h after ﬁnal dosing (Fig. 3b).
3.5. Safety results
In the single administration study, there was no clinically sig-
niﬁcant adverse event. Angular bleeding and epistaxis were re-
ported in 1 subject each in the 30 mg group, however, both events
were not serious and were promptly resolved without the need for
treatment. In addition, fecal occult blood was reported in 3 subjects
(one each in 5, 10, and 30mg groups), and occult blood in urine was
reported in 2 subjects (one each in 10 and 20 mg groups), but both
events were transient and required no treatment.In themultiple administration study, regarding bleeding-related
adverse events, epistaxis was reported in 4 subjects (one in 5 mg
group and 3 subjects in 7.5 mg group), gingival bleeding, hemor-
rhoidal bleeding, and petechiae were reported in one subject of the
7.5 mg group, 7.5 mg group, and 2.5 mg group, respectively. All of
the adverse events were mild and resolved promptly without any
treatment. There was no dose-dependent increase in the incidence
of such bleeding events.
4. Discussion
In the previous study, the mean weight among individuals
receiving prasugrel was comparable among Caucasians (77.4 kg)
Fig. 3. Time course of bleeding time after a) single and b) multiple administration of prasugrel.
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but was lower in Asians (64.7 kg) [10]. Active metabolite exposure
was 45% higher in Asians than in Caucasians. The higher exposure
to prasugrel's active metabolite has been associated with more
extensive platelet inhibition in Asians than in Caucasians [14,15].
After accounting for the 9-kg weight difference between the Asians
and Caucasians, the 90% CI for the difference in AUC0-t was small
and fell within the equivalence boundaries [10]. Considered
together, it is thought that Japanese should use a lower dose than
that prescribed in the USA and EU. We assessed the safety, phar-
macokinetics, and pharmacodynamics of lower doses of prasugrel
in healthy Japanese males in this study.
After a single administration of prasugrel of 2e30 mg to healthy
adult males, the plasma concentrations of the active metabolite
rapidly increased, and reached their maximum at 30 min after
administration. The AUC0-tz, AUC0-inf, and Cmax tended to increase
with dose. Prasugrel at 5 mg and higher doses prevented ADP-
induced platelet aggregation dose-dependently. The inhibitory ef-
fect persisted even after the elimination of the active metabolite
from plasma, and gradually decreased up to 168 h after adminis-
tration. Moreover, the t1/2 increased with dose. This may be partly
caused by time to reach the limit of quantitation (LOQ) of the
plasma concentration at each dose; at a lower dose, the plasma
concentration of the active metabolite reaches LOQ more quickly
than at a higher dose, resulting in a shorter elimination phase with
a low dose. In a single-dose study of prasugrel, time to reach LOQ of
the plasma concentration of the active metabolite was 24 h in 6/8
patients taking 30 mg, whereas, in patients taking 2 mg, it was 4 h
in 4/8 patients and 2 h in 4/8 patients.
The inhibition of ADP-induced platelet aggregation reached its
peak after a single dose of 30 mg, and 20 mg prasugrel showed a
nearly equivalent platelet inhibitory effect. IPA in response to ADP
20 mMat 4 h after dosingwas 64.8% in the 20-mg group and 71.2% in
the 30-mg group. The results are comparable to those reported in a
study of healthy Caucasian individuals who took prasugrel 60 mg;
IPA at 4 h after dosing was 62.4% (data not shown) [16]. Therefore,
we consider that doses used in the present study (20 mg and
30 mg) were sufﬁcient to exert antiplatelet effects.
Adverse events were observed in all groups, but there was no
dose group where the number of adverse events was clearly higher
than placebo. All of the study drug-related adverse events observed
in the present study were mild, and there were no clinically sig-
niﬁcant bleeding-related adverse events. The bleeding time was
prolonged by prasugrel administration. This prolongation was
considered to be a result of the antiplatelet effect of prasugrel.
However, this effect on the bleeding time was not signiﬁcant
because there were no clinically important adverse events.Therefore, a single administration of prasugrel at a dose of up to
30 mg is considered to be well tolerated and unlikely to result in
any safety issues.
In the multiple administration study, the plasma concentration
of the active metabolite increased rapidly and reached a maximum
at 30 min after administration. The elimination was also rapid, as
seen in the single administration study. The plasma concentration
increased with doses of 2.5e7.5 mg, on both Day 1 and Day 7.
However, the concentration in the 10-mg group was lower than in
the 7.5-mg group. The percentage coefﬁcients of variation of AUCtau
at Day 7 were 20.0%, 12.5%, and 29.5% in the 5-, 7.5-, and 10-mg
groups, respectively. In the 10-mg group, variation among in-
dividuals was rather large. The reason why the plasma concentra-
tion in the 10-mg group was low is unclear; however, it may have
been caused by variations in pharmacokinetics in individuals.
As for the platelet aggregation induced by ADP, a signiﬁcant
inhibitory effect was observed. The inhibitory effect was higher on
Day 7 than Day 1, regardless of the similar pharmacokinetics on
these days, suggesting that the pharmacological effect did accu-
mulate due to the irreversible binding of prasugrel.
In the dose range examined in the present study, the inhibitory
effect of platelet aggregation increased with dose, but it did not
show a major difference between the 7.5-mg and 10-mg groups.
This indicates that there is a trend for saturation of the effect. It is
suggested that a maintenance dose of less than 10 mg is sufﬁcient
for Japanese subjects.
Althoughmild adverse events were observed in all groups, none
were of clinical signiﬁcance. Therefore, multiple oral administra-
tion of prasugrel from 2.5 to 10 mg was considered to be well
tolerated.
In conclusion, the plasma concentration of the active metabolite
of prasugrel was rapidly increased after administration, and a single
oral administration of prasugrel at a dose of up to 30 mg and a
multiple administration of prasugrel at a dose of up to 10 mg are
tolerated in Japanese healthy subjects.Conﬂict of interest
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